Check Out Royalty Pharma plc (RPRX)’s Trade Data Rather Than the Analysts’ Views

With 3.62 million shares changed hands, the volume of the stock remained heavier than its average volume of 2.48 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $30.34 whereas the lowest price it dropped to was $29.29. The 52-week range on RPRX shows that it touched its highest point at $38.79 and its lowest point at $25.92 during that stretch. It currently has a 1-year price target of $43.57. With its current market cap of 13.17 billion, RPRX has annualized dividend of $0.89 while the current yield stands at 3.02%. Beta for the stock currently stands at 0.43.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of RPRX was up-trending over the past week, with a rise of 3.31%, but this was up by 4.90% over a month. Three-month performance surged to 5.58% while six-month performance fell -3.99%. The stock lost -23.36% in the past year, while it has gained 4.41% so far this year. A look at the trailing 12-month EPS for RPRX yields 0.40 with Next year EPS estimates of 3.83. For the next quarter, that number is 0.99. This implies an EPS growth rate of 14.52% for this year and -9.25% for next year. EPS is expected to grow by 3.20% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -45.28%.

Float and Shares Shorts:

At present, 443.17 million RPRX shares are outstanding with a float of 381.07 million shares on hand for trading. On Jan 11, 2024, short shares totaled 10.19 million, which was 2.28% higher than short shares on Dec 14, 2023. In addition to RXRX as the firm’s Recursion Pharmaceuticals, Inc., CPRX serves as its Catalyst Pharmaceuticals, Inc.

Institutional Ownership:

Through their ownership of 69.82% of RPRX’s outstanding shares, institutional investors have majority control over the company.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for RPRX since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With RPRX analysts setting a high price target of $56.00 and a low target of $37.00, the average target price over the next 12 months is $43.57. Based on these targets, RPRX could surge 90.93% to reach the target high and rise by 26.15% to reach the target low. Reaching the average price target will result in a growth of 48.55% from current levels.

Dividends & Yield:

In terms of dividends, RPRX has a current ratio of $0.84, which is $0.84 over the trailing 12-months, while a dividend of $– is likely to be paid on average over the next five years. Dividend yield is another indicator that appeals to many investors, and RPRX currently yields $2.73. In the past year, RPRX’s dividend yield has been $2.73, but when looking at the stock over the past five years, its yield has been $–. Accordingly, RPRX has a current buyback yield of $2.1. This was $2.1 for the TTM, and it was $– for the past five years.